My question on Turing/Daraprim isn't why they jacked the price $700. It's why they didn't raise it even more.http://www.vox.com/2015/9/22/9366721/daraprim-price-shkreli-turing …
@Roysploitation They definitely could but the drug treats a relatively rare disease, so probably not worth the start-up costs.
-
-
@sarahkliff@Roysploitation NYT says they exploit FDA control regs to keep out of generic mfrs' hands. Would love to hear more about thatThanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
@sarahkliff@Roysploitation correct. Also, because they have shareholders and don't want bad press.Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.